Wanbury Limited has reported a robust performance for the quarter and nine months ended December 31, 2025, with a sharp improvement in profitability driven by its Active Pharmaceutical Ingredients (API) business and operational efficiencies.
Revenue from operations in Q3 FY26 stood at Rs. 162.4 crore, up from Rs. 133.5 crore in Q3 FY25, translating into a year-on-year growth of 21.7 per cent, led by higher API volumes, improved capacity utilisation at key manufacturing facilities and steady traction in the formulations segment. EBITDA, including other income, rose 81.7 per cent to Rs. 26.9 crore against Rs. 14.8 crore in the same quarter last year, supported by operating leverage, better procurement strategies, higher product yields and enhanced solvent recovery systems. EBITDA margin expanded to 16.5 per cent from 11.0 per cent in Q3 FY25, underscoring the improved quality of earnings.
Profit after tax (PAT) for the quarter jumped to Rs. 15.8 crore from Rs. 1.2 crore a year ago, marking a 1,194.3 per cent increase, aided by strong operating performance, margin expansion, improved cost efficiencies and lower finance costs. PAT margin improved to 9.7 per cent in Q3 FY26 compared to 0.9 per cent in the corresponding quarter of the previous year.
For the nine months ended December 31, 2025, revenue from operations was Rs. 485.7 crore, up 13.6 per cent from Rs. 427.5 crore in 9M FY25, primarily on account of volume-led growth in APIs and stable performance in formulations. EBITDA for 9M FY26 stood at Rs. 77.6 crore versus Rs. 48.3 crore in the previous year, reflecting a 60.6 per cent rise on the back of sustained operational efficiencies, an improved product mix, better capacity utilisation and continued cost optimisation initiatives. EBITDA margin for the period improved to 16.0 per cent from 11.3 per cent in 9M FY25. PAT for 9M FY26 was Rs. 44.4 crore, up from Rs. 10.3 crore, an increase of 332.5 per cent, while PAT margin expanded to 9.1 per cent from 2.4 per cent.
Commenting on the company’s performance, Mr. Mohan Rayana, Director, Wanbury Ltd., said that the quarter underlines the strength of the company’s core API franchise and focus on profitable growth. “Q3 FY26 revenue grew 22 per cent year-on-year and 9M FY26 revenue grew 14 per cent, driven by strong demand and higher volumes in our API business alongside moderate but steady growth in formulations,” he said. “EBITDA for the quarter increased to Rs. 26.9 crore and to Rs. 77.6 crore for the nine months, an improvement of 81.7 per cent and 60.6 per cent respectively, supported by sales of high-margin SKUs, an improved product mix, higher yields, enhanced solvent recovery and better procurement.”
He further noted that profit after tax has seen a step change. “Q3 FY26 PAT improved to Rs. 15.8 crore from Rs. 1.2 crore in Q3 FY25 and 9M FY26 PAT increased to Rs. 44.4 crore from Rs. 10.3 crore, reflecting the benefit of strong operations and reduced finance costs,” Mr. Rayana added.
On the business outlook, Mr. Rayana highlighted the momentum in the API portfolio. “We have completed commercial invoicing and shipment of a high-potency anaesthetic API to a European customer from our cutting-edge Tanuku facility in Q3 FY26,” he said. “With upcoming launches in antidiabetic, anticoagulant, cough suppressant and antidepressant APIs, Wanbury is well positioned for growth in the coming years.”
The formulations business, which has turned EBITDA positive in Q3 and 9M FY26, is also gaining traction. The company reported encouraging results from the recent launch of nutritional supplement C-Red and other products, and is building a healthy pipeline for expansion into new therapeutic categories.
